Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab. Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks. Results: The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the ‘mother patch’ group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the ‘non-mother patch’ group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores. Conclusions: The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.

Rapid efficacy of riSankizumab in pretibial psoriasis invOLVEment. RESOLVE / Bernardini, Nicoletta; Skroza, Nevena; Atzori, Laura; Mugheddu, Cristina; Megna, Matteo; Cacciapuoti, Sara; Ortoncelli, Michela; Montesu, Maria A; Carpentieri, Antonio; Carriero, Martino; Atzori, Maria G; Addis, Gianmario; Balestri, Riccardo; Rech, Giulia; Bruni, Pierluigi; Papini, Manuela; Potenza, Concetta. - In: DRUGS IN CONTEXT. - ISSN 1740-4398. - 13:(2024). [10.7573/dic.2024-6-3]

Rapid efficacy of riSankizumab in pretibial psoriasis invOLVEment. RESOLVE

Bernardini, Nicoletta
;
Skroza, Nevena;Atzori, Laura;Carpentieri, Antonio;Potenza, Concetta
2024

Abstract

Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab. Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks. Results: The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the ‘mother patch’ group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the ‘non-mother patch’ group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores. Conclusions: The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.
2024
il-23 inhibitors; difficult-to-treat-areas; pretibial; psoriasis
01 Pubblicazione su rivista::01a Articolo in rivista
Rapid efficacy of riSankizumab in pretibial psoriasis invOLVEment. RESOLVE / Bernardini, Nicoletta; Skroza, Nevena; Atzori, Laura; Mugheddu, Cristina; Megna, Matteo; Cacciapuoti, Sara; Ortoncelli, Michela; Montesu, Maria A; Carpentieri, Antonio; Carriero, Martino; Atzori, Maria G; Addis, Gianmario; Balestri, Riccardo; Rech, Giulia; Bruni, Pierluigi; Papini, Manuela; Potenza, Concetta. - In: DRUGS IN CONTEXT. - ISSN 1740-4398. - 13:(2024). [10.7573/dic.2024-6-3]
File allegati a questo prodotto
File Dimensione Formato  
Bernardini_Rapid-efficacy_2024.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 453.7 kB
Formato Adobe PDF
453.7 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1735735
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact